Heidelberg Pharma AG (WBO:HPHA) LT-Debt-to-Total-Asset: 0.00 (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:HPHA Heidelberg Pharma AG WBO:HPHA
10 GF Score
Price €2.55
GF Value €2.87
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Heidelberg Pharma AG LT-Debt-to-Total-Asset?

Heidelberg Pharma AG WBO:HPHA 10 LT-Debt-to-Total-Asset is 0.00 as of May. 2026. GuruFocus rates WBO:HPHA with a GF Score™ of 10/100 and a GF Value™ of €2.87 (Modestly Undervalued). The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Heidelberg Pharma AG's long-term debt to total assests ratio for the quarter that ended in May. 2026 was 0.00.

Heidelberg Pharma AG's long-term debt to total assets ratio increased from May. 2025 (0.00) to May. 2026 (0.00). It may suggest that Heidelberg Pharma AG is progressively becoming more dependent on debt to grow their business.

Heidelberg Pharma AG  (WBO:HPHA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Heidelberg Pharma AG LT-Debt-to-Total-Asset Related Terms

Heidelberg Pharma AG LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Heidelberg Pharma AG's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Heidelberg Pharma AG LT-Debt-to-Total-Asset Chart

Heidelberg Pharma AG Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Heidelberg Pharma AG Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
WBO:HPHA
10GF Score
Heidelberg Pharma AG WBO:HPHA
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Heidelberg Pharma AG LT-Debt-to-Total-Asset Calculation

Heidelberg Pharma AG's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Nov. 2025 is calculated as

LT Debt to Total Assets (A: Nov. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Nov. 2025 )/Total Assets (A: Nov. 2025 )
=0.013/38.136
=0.00

Heidelberg Pharma AG's Long-Term Debt to Total Asset Ratio for the quarter that ended in May. 2026 is calculated as

LT Debt to Total Assets (Q: May. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: May. 2026 )/Total Assets (Q: May. 2026 )
=0.046/46.895
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Heidelberg Pharma AG (WBO:HPHA) has a LT-Debt-to-Total-Asset of 0.00 as of May. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Heidelberg Pharma AG and its competitors.
Is Heidelberg Pharma AG's LT-Debt-to-Total-Asset too high?
Heidelberg Pharma AG's current LT-Debt-to-Total-Asset is 0.00. Overall, Heidelberg Pharma AG has a GF Score™ of 10/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's LT-Debt-to-Total-Asset compare to VRTX and REGN?
Heidelberg Pharma AG's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Heidelberg Pharma AG and its competitors. Heidelberg Pharma AG's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Based on GuruFocus' analysis, Heidelberg Pharma AG (WBO:HPHA) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.87, compared to a current price of €2.55 — trading 11.1% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. Heidelberg Pharma AG's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Heidelberg Pharma AG (WBO:HPHA), the current LT-Debt-to-Total-Asset is 0.00 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Heidelberg Pharma AG (WBO:HPHA) Overvalued in 2026?

Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be undervalued. The current stock price of €2.55 is trading 11.1% below its estimated GF Value™ of €2.87. GuruFocus considers Heidelberg Pharma AG to be Modestly Undervalued.

Key valuation signals for WBO:HPHA:

  • LT-Debt-to-Total-Asset: 0.00
  • GF Value™: €2.87 vs. price of €2.55 (11.1% below fair value)
  • GF Score™: 10/100 with 5 warning signs

No single metric tells the full story. See the WBO:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Heidelberg Pharma AG Business Description

Other Exchanges 0QW5:UKHPHA:Germany
Address Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
10GF Score

Get the complete analysis for WBO:HPHA

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.55
Price
€2.87
GF Value